CIK 0001783328
- Non-accelerated filer
- Smaller reporting company
- Emerging growth company
TScan Therapeutics, Inc.
Sign in to watch- Ticker
- TCRX
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 825282075
- Phone
- +1 857-399-9500
- Business address
- 830 WINTER STREET, WALTHAM, MA, 02451
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2022-06-01 | Harel Ittai Director | Grant or award · Stock Option (Right to Buy) | +9,146 | 9,146 | ||
| 2022-05-18 | SOUTHWELL DAVID P Chief Executive Officer | Purchase | +15,000 | $3.62 | $54K | 161,569 |
| 2022-05-18 | SOUTHWELL DAVID P Chief Executive Officer | Purchase | +10,000 | $3.55 | $35K | 171,569 |
| 2022-05-11 | BAKER BROS. ADVISORS LP Director | Purchase | +2,882 | $1.99 | $6K | 256,209 |
| 2022-05-11 | BAKER BROS. ADVISORS LP Director | Purchase | +22,983 | $1.99 | $46K | 2,528,583 |
| 2022-05-10 | BAKER BROS. ADVISORS LP Director | Purchase | +40,800 | $1.70 | $69K | 145,498 |
| 2022-05-10 | BAKER BROS. ADVISORS LP Director | Purchase | +325,373 | $1.70 | $553K | 1,645,675 |
| 2022-05-10 | BAKER BROS. ADVISORS LP Director | Purchase | +12,769 | $1.93 | $25K | 158,267 |
| 2022-05-10 | BAKER BROS. ADVISORS LP Director | Purchase | +101,831 | $1.93 | $197K | 1,747,506 |
| 2022-05-10 | BAKER BROS. ADVISORS LP Director | Purchase | +95,060 | $1.95 | $185K | 253,327 |
| 2022-05-10 | BAKER BROS. ADVISORS LP Director | Purchase | +758,094 | $1.95 | $1.5M | 2,505,600 |
| 2022-03-24 | Silver Brian M. Chief Financial Officer | Purchase | +15,000 | $3.40 | $51K | 26,885 |
| 2022-01-18 | Desmarais William Chief Business Officer | Grant or award · Stock Option (Right to Buy) | +50,000 | 50,000 | ||
| 2022-01-18 | MacBeath Gavin Chief Scientific Officer | Grant or award · Stock Option (Right to Buy) | +140,000 | 140,000 | ||
| 2022-01-18 | Silver Brian M. Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +115,000 | 115,000 | ||
| 2022-01-18 | SOUTHWELL DAVID P Chief Executive Officer | Grant or award · Stock Option (Right to Buy) | +275,000 | 275,000 | ||
| 2022-01-18 | ZDRAVESKI ZORAN Chief Legal Officer | Grant or award · Stock Option (Right to Buy) | +85,000 | 85,000 | ||
| 2021-12-23 | SOUTHWELL DAVID P Chief Executive Officer | Option exercise | +48,670 | $1.97 | $96K | 146,569 |
| 2021-12-23 | SOUTHWELL DAVID P Chief Executive Officer | Option exercise · Stock Option (Right to Buy) | −48,670 | 21,161 | ||
| 2021-09-23 | ZDRAVESKI ZORAN Chief Legal Officer | Purchase | +4,716 | $7.48 | $35K | 4,716 |
Page 6 of 8 · 144 trades